Effect of Daily Consumption of Glycomacropeptide on gut microbiome and blood functional proteome in irritable bowel syndrome

The company Oregon State University is commencing recruitment for the clinical trial of the Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome.

The trial officially began on the January 1, 2022 and is planned to complete on September 2024.

This study investigates the use of glycomacropeptide (GMP) as a means to manipulate the gut microbiome, metabolome and protein profile of subjects with irritable bowel syndrome (IBS).

The population that can be enrolled into this study includes:

• Fluent in English - IBS diagnosis with Rome IV criteria - People who have a primary care provider Exclusion Criteria: - Lactose or milk protein intolerance - Any known other gastrointestinal disease or disorder beyond IBS, or major gastrointestinal surgery - Habitual use of laxatives or antacids - Pregnant or nursing. - Use of pre or probiotics within one month prior to the study - Use of antibiotics within one month prior to the study.

Patients with the following pathologies:

• Lactose or milk protein intolerance - Any known other gastrointestinal disease or disorder beyond IBS, or major gastrointestinal surgery - Habitual use of laxatives or antacids - Pregnant or nursing. - Use of pre or probiotics within one month prior to the study - Use of antibiotics within one month prior to the study.

are excluded from participation.

BUILD Dairy, Agropur are the collaborators in this clinical trial.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05482464.